Kenneth Getz, MBA
Executive Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine
It is my pleasure to welcome you to the Tufts Center for the Study of Drug Development website.
Since 1976, we have provided scholarly assessments of the time, cost, and risk of drug development innovation as well as the trends, factors, and practices impacting clinical trial execution. Today, the Tufts Center for the Study of Drug Development (Tufts CSDD) at Tufts University School of Medicine is the only multidisciplinary academic research center dedicated to optimizing drug development performance, efficiency, and economics through robust, data-driven assessments and analyses.
Because of our reputation for scholarly and objective insights drawn from hard evidence, we are frequently asked to provide public testimony at U.S. Congressional and state-level hearings; interact with international regulatory agencies and health authorities; prepare executive reports and white papers; and speak at conferences, webinars, committee meetings, and public forums.
Each year Tufts CSDD conducts independent research studies funded by foundations, government agencies, professional associations, and the private sector. Tufts CSDD also conducts several working group studies annually involving the input and participation of organizations active throughout the clinical research enterprise.
The challenges of developing pharmaceutical innovations are intensifying as R&D complexity, customization, and fragmentation increase. All stakeholders involved — pharmaceutical and biotechnology companies, regulators, policy-makers, public and private investigative sites and site networks, technology companies, investors, and contract service providers — need data and actionable insights to improve drug development performance, efficiency, and economics. The work of the Tufts Center could not be more important or relevant.
Please contact us via email at firstname.lastname@example.org or phone at 617-636-2170 for more information.
Kenneth Getz, MBA
Executive Director and Research Professor